Nathan Barefoot, Priya J Desai, Anna van Dorsten, Elena Quinonez Del Cid, Katrina Bootes, Ismail Khaderi, Ezer H Benaim, Jackson Vuncannon, Cristine Klatt-Cromwell, Charles S Ebert, Raj S Kasthuri, Brent A Senior, Brian D Thorp, Adam J Kimple
Bevacizumab reduced epistaxis-related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.